We are doing our best to realize the hopes and dreams of humankind: ‘perpetual youth’ and ‘a lifetime of health.’ Our results in these efforts include the completion of KOREF; the first completion of a genome map by a Korean; the world’s first completed genome map of a tiger, whale, horse, and leopard; the release of a high-speed, automatic liquid biopsy product; CD-PRIME; and the certification of new medical technology and a class 3 permit for an AmoyDx ROS1 mutations detection kit from the Ministry of Food and Drug Safety. By working on such tasks as the early diagnosis and prediction of cancer, the selective prediction of rare diseases and the treatment of genetic disorders with precision medicine, we aim to become a global company specializing in genomic analysis based on genome ICT.
We are continuing to develop new analytical technologies such as AI (artificial intelligence) algorithms and multi-omics. We have established a cooperative system with world-class scholars such as George McDonald Church and Prashant Gulab Ram Mali to secure global competitiveness in the genetic analysis market.
Through this cooperative system, the company will provide services in early diagnosis for cancer/diseases, medical and health care, customized precision medicine, and gene therapy.
Thank you from Clinomics Executives.
